Merck KGaA, Darmstadt, Germany, joins forces with Versant Ventures to launch Saturnus Bio, an exciting new biotech venture committed to revolutionizing treatments for rare genetic cardiomyopathies and expanding the frontier of groundbreaking therapies
Exciting news from Japan! The Ministry of Health, Labour and Welfare (MHLW) has officially approved Sarepta Therapeutics' groundbreaking gene therapy for Duchenne muscular dystrophy (DMD). This pivotal decision opens up new horizons for patients in Japan battling this challenging condition, offering hope and enhanced treatment options like never before.
Chiesi has invested €430 million in a new facility in Italy, aiming to bolster its production capabilities. Meanwhile, Bharat Biotech has inaugurated its first cell and gene therapy (CGT) site in India, marking a significant advancement in the region's biopharmaceutical landscape.
